Dopamine receptor agonists reverse behavioral abnormalities of α-synuclein transgenic mouse, a new model of Parkinson's disease

2008 ◽  
Vol 86 (3) ◽  
pp. 640-646 ◽  
Author(s):  
Masaki Wakamatsu ◽  
Shingo Iwata ◽  
Takeo Funakoshi ◽  
Makoto Yoshimoto
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptor ◽  
Transgenic Mouse ◽  
Dopamine Receptor Agonists ◽  
New Model ◽  
Receptor Agonists ◽  
Behavioral Abnormalities

scholarly journals Adenosine Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Carina J. Bleickardt ◽  
Abigail L. LaShomb ◽  
Carrie E. Merkel ◽  
Robert A. Hodgson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Dopamine Receptor ◽  
Prepulse Inhibition ◽  
Adenosine Receptor ◽  
Side Effect ◽  
Side Effect Profile ◽  
Dopamine Receptor Agonists ◽  
Receptor Agonists

Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists. However, these treatments induce neuropsychiatric side effects. Psychosis, characterized by delusions and hallucinations, is one of the most serious such side effects. Adenosine receptor antagonism is a nondopaminergic treatment for PD with clinical and preclinical efficacy. The present studies assessed antagonists SCH 412348 and istradefylline in rodent prepulse inhibition (PPI), a model of psychosis. Dopamine receptor agonists pramipexole (0.3–3 mg/kg), pergolide (0.3–3 mg/kg), and apomorphine (0.3–3 mg/kg) significantly disrupted PPI; ropinirole (1–30 mg/kg) had no effect; L-dopa (100–300 mg/kg) disrupted rat but not mouse PPI. SCH 412348 (0.3–3 mg/kg) did not disrupt rodent PPI; istradefylline (0.1–1 mg/kg) marginally disrupted mouse but not rat PPI. These results suggest that antagonists, unlike dopamine agonists, have an improved neuropsychiatric side effect profile.

Dopamine Receptor Agonists: New Formulations and New Potentials in the Treatment of Parkinson’s Disease

2016 ◽  
Vol 46 (8) ◽  
pp. 971-977
Author(s):  
E. A. Katunina ◽  
N. V. Titova ◽  
Yu. N. Bezdol’nyi ◽  
R. K. Shikkerimov ◽  
M. G. Gasanov ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptor ◽  
Dopamine Receptor Agonists ◽  
Receptor Agonists

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

2011 ◽  
Vol 26 (5) ◽  
pp. 801-806 ◽  
Author(s):  
Vibeke Guldbrand Rasmussen ◽  
Karen Østergaard ◽  
Erik Dupont ◽  
Steen Hvitfeldt Poulsen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptor ◽  
Valvular Regurgitation ◽  
Dopamine Receptor Agonists ◽  
Receptor Agonists
Sign in / Sign up

Export Citation Format

Share Document